CL2018003431A1 - Tratamiento de la enfermedad de parkinson. - Google Patents

Tratamiento de la enfermedad de parkinson.

Info

Publication number
CL2018003431A1
CL2018003431A1 CL2018003431A CL2018003431A CL2018003431A1 CL 2018003431 A1 CL2018003431 A1 CL 2018003431A1 CL 2018003431 A CL2018003431 A CL 2018003431A CL 2018003431 A CL2018003431 A CL 2018003431A CL 2018003431 A1 CL2018003431 A1 CL 2018003431A1
Authority
CL
Chile
Prior art keywords
disease
parkinson
treatment
arilacetilen
hydrazide
Prior art date
Application number
CL2018003431A
Other languages
English (en)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of CL2018003431A1 publication Critical patent/CL2018003431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

USO DE COMPUESTOS DERIVADOS DE DI(HETERO)ARILACETILEN HIDRAZIDA PARA LA PREPARACIÓN DE UN MEDICAMENTO ÚTIL PARA TRATAR O PREVENIR LA ENFERMEDAD DE PARKINSON.
CL2018003431A 2016-06-02 2018-11-30 Tratamiento de la enfermedad de parkinson. CL2018003431A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02

Publications (1)

Publication Number Publication Date
CL2018003431A1 true CL2018003431A1 (es) 2019-05-10

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003431A CL2018003431A1 (es) 2016-06-02 2018-11-30 Tratamiento de la enfermedad de parkinson.

Country Status (24)

Country Link
US (4) US10849887B2 (es)
EP (2) EP4085912A1 (es)
JP (1) JP6974357B2 (es)
KR (1) KR102508288B1 (es)
CN (1) CN109475539B (es)
AU (1) AU2017273415B2 (es)
CA (1) CA3024976A1 (es)
CL (1) CL2018003431A1 (es)
DK (1) DK3463351T3 (es)
ES (1) ES2914782T3 (es)
HR (1) HRP20220683T1 (es)
HU (1) HUE059387T2 (es)
IL (1) IL263188B (es)
LT (1) LT3463351T (es)
MX (1) MX2018014944A (es)
MY (1) MY193754A (es)
PH (1) PH12018502457B1 (es)
PL (1) PL3463351T3 (es)
PT (1) PT3463351T (es)
RS (1) RS63243B1 (es)
SG (1) SG11201810294QA (es)
SI (1) SI3463351T1 (es)
UA (1) UA123018C2 (es)
WO (1) WO2017208267A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
WO2017208267A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
EA202193211A1 (ru) 2019-06-11 2022-03-30 Сан Фарма Эдванст Рисерч Компани Лтд. Лечение синуклеопатий
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
JP2023536440A (ja) 2020-07-31 2023-08-25 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド アルツハイマー病の治療のためのｎ’－（２－クロロ－６－メチルベンゾイル）－４－メチル－３－［２－（３－キノリル）エチニル］－ベンゾヒドラジド
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012098416A1 (en) 2011-01-21 2012-07-26 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
JP6689887B2 (ja) * 2015-05-18 2020-04-28 スン プハルマ アドバンセド リサーチ カンパニー リミテド 新規アミドヘテロアリールアロイルヒドラジドエチン
WO2017208267A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
US20210015805A1 (en) 2021-01-21
ES2914782T3 (es) 2022-06-16
BR112018074439A2 (pt) 2019-03-06
EP4085912A1 (en) 2022-11-09
IL263188A (en) 2018-12-31
JP2019520344A (ja) 2019-07-18
IL263188B (en) 2021-08-31
MY193754A (en) 2022-10-27
UA123018C2 (uk) 2021-02-03
MX2018014944A (es) 2019-03-07
AU2017273415B2 (en) 2023-01-19
EP3463351A1 (en) 2019-04-10
RS63243B1 (sr) 2022-06-30
JP6974357B2 (ja) 2021-12-01
US11813252B2 (en) 2023-11-14
EP3463351B1 (en) 2022-04-27
US20240066014A1 (en) 2024-02-29
US10849887B2 (en) 2020-12-01
KR102508288B1 (ko) 2023-03-09
HUE059387T2 (hu) 2022-11-28
PL3463351T3 (pl) 2022-06-20
KR20190015257A (ko) 2019-02-13
DK3463351T3 (da) 2022-06-07
CN109475539A (zh) 2019-03-15
CN109475539B (zh) 2021-12-28
US20220273632A1 (en) 2022-09-01
SI3463351T1 (sl) 2022-07-29
US11583522B2 (en) 2023-02-21
AU2017273415A1 (en) 2018-12-06
PT3463351T (pt) 2022-06-02
LT3463351T (lt) 2022-06-10
PH12018502457A1 (en) 2019-10-21
CA3024976A1 (en) 2017-12-07
PH12018502457B1 (en) 2019-10-21
US20190275017A1 (en) 2019-09-12
SG11201810294QA (en) 2018-12-28
WO2017208267A1 (en) 2017-12-07
HRP20220683T1 (hr) 2022-07-08

Similar Documents

Publication Publication Date Title
CL2018003431A1 (es) Tratamiento de la enfermedad de parkinson.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
MY196576A (en) Amino Pyrimidine SSAO Inhibitors
BR112017002001A2 (pt) compostos e composição farmacêutica
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EA201990400A1 (ru) Соединения и композиции и их применение
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
TW201625535A (en) Inhibitors of histone demethylases
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
EA202090414A1 (ru) Соединения и их применение
CY1122172T1 (el) Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease